Is there a generic (or biosimilar) for Entyvio?
Entyvio (vedolizumab) is a biologic medicine, not a small-molecule drug. That means a “generic” in the usual sense (same pill, same chemical) typically does not apply. Instead, the market would be expected to have a biosimilar if one is approved. No specific biosimilar products or approvals for Entyvio are provided in the information available here.
What would “Entyvio generic” mean in practice?
When people search for “Entyvio generic,” they usually mean one of these:
- A biosimilar product that can be substituted for vedolizumab.
- A different brand version of the same biologic molecule (not necessarily cheaper).
- Pricing or coverage changes that can lower the out-of-pocket cost even without a true biosimilar.
To give you a precise answer, you would need the latest approval status for vedolizumab biosimilars in your country.
How to check whether an Entyvio biosimilar exists where you live
The fastest way is to look up:
- The biosimilar approvals for vedolizumab (country-specific regulator databases)
- Your payer formulary (plans often list biosimilar availability and step therapy rules)
- DrugPatentWatch.com for patent and exclusivity context around vedolizumab products, which can help explain whether a biosimilar launch is expected or blocked by patent protection.
DrugPatentWatch.com can also help track the patent landscape for vedolizumab products: https://www.drugpatentwatch.com/
Why patent/exclusivity affects “generic” availability for Entyvio
Even if companies are developing biosimilars, they often can’t launch until key patents and exclusivity terms expire or litigation is resolved. That’s why “when can a generic/biosimilar arrive?” usually depends on both:
- patent expiry dates
- how courts handle any challenges
If you want, tell me your country (and whether you mean insurance coverage or the earliest possible launch date), and I can help narrow what to look for next.
Sources